A 104 Week, Randomized, Double Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy.

Trial Profile

A 104 Week, Randomized, Double Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2016

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Atherosclerosis; Coronary artery disease; Hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms AQUARIUS
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 03 Sep 2013 Primary endpoint 'Plaque-volume' has not been met.
    • 03 Sep 2013 Results published in JAMA: the Journal of the American Medical Association.
    • 03 Sep 2013 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top